Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Electromed, Inc. filings document formal disclosures for a Minnesota operating company focused on airway clearance technologies. Recent Form 8-K reports furnish quarterly financial results, Regulation FD investor presentations, share repurchase authorization disclosures, and material financing information tied to a senior secured revolving credit facility.
The company's proxy and shareholder-vote filings cover director elections, auditor ratification, advisory executive compensation votes, board and governance matters, and equity-compensation disclosures. These records also describe capital-allocation actions, debt covenants, financial condition updates, and exhibit materials associated with press releases, credit agreements, and investor presentations.
Electromed, Inc. delivered strong results for the quarter ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was led by homecare sales and faster expansion in the hospital market.
Quarterly net income rose to $3.0 million from $1.9 million, while diluted EPS increased to $0.35 from $0.21, reflecting higher volumes and improved net revenues per device. Gross margin remained high at about 79%, helping operating income grow faster than sales.
The company ended the period with $17.0 million in cash and no borrowings on its $10 million revolving credit facility, and has active share repurchases, having bought back 151,911 shares for $3.9 million under a $10 million authorization.
Electromed, Inc. reported record results for its fiscal Q3 ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was driven mainly by its direct homecare business, where revenue rose 18.6% to $16.7 million on more sales reps, higher productivity, and greater revenue per representative.
Gross profit increased to $14.6 million, with gross margin improving to 78.8%. Operating income jumped 76.0% to $3.8 million, lifting operating margin to 20.3%. Net income grew 58.8% to $3.0 million, or $0.35 per diluted share, compared with $0.21.
The company ended the quarter with $17.0 million in cash, no debt, working capital of $40.0 million and shareholders’ equity of $49.2 million. Over the nine-month period, Electromed generated $6.7 million in operating cash flow while repurchasing $3.9 million of its common stock.
Electromed Inc: The Vanguard Group filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of 0 shares (0%) of Common Stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately "in accordance with SEC Release No. 34-39538 (January 12, 1998)".
The amendment lists Vanguard's address and shows no sole or shared voting or dispositive power over Electromed shares. The signature block is by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Electromed, Inc. reported strong growth for the quarter ended December 31, 2025. Net revenues rose to $18,897,000 from $16,255,000, driven mainly by higher homecare sales and increased productivity per sales representative. Gross margin remained high at about 78% of net revenues.
Net income increased to $2,761,000, up from $1,968,000, with diluted earnings per share improving to $0.32 from $0.22. For the first six months, revenue reached $35,784,000 and net income $4,897,000, both well above the prior year.
The company ended the period with cash and cash equivalents of $13,791,000 and total shareholders’ equity of $45,439,000. It entered a new $10,000,000 secured revolving credit facility with no borrowings outstanding and continued its stock repurchase program, retiring 146,441 shares at an average price of $25.72 per share.
Electromed, Inc. reported record fiscal 2026 second-quarter results, with net revenues of $18.9 million, up 16.3% from $16.3 million a year earlier. Direct homecare revenue rose 18.4% to $17.3 million, driven by more sales representatives and higher revenue per rep, which annualized at $1.2 million, above the company’s $1.0–$1.1 million target range.
Gross profit increased to $14.8 million and gross margin edged up to 78.4%. Operating income grew 42.4% to $3.6 million, lifting the operating margin to 19.2%. Net income rose 40.3% to $2.8 million, or $0.32 per diluted share, marking the 13th consecutive quarter of year-over-year revenue and net income growth.
As of December 31, 2025, Electromed held $13.8 million in cash, $36.2 million in working capital, and no debt, with shareholders’ equity of $45.4 million. Cash declined by $1.5 million over six months, mainly due to $3.8 million of share repurchases, partly offset by $3.2 million of positive operating cash flow.
Electromed, Inc. entered into a new Credit Agreement with BMO Bank N.A., providing a senior secured revolving credit facility of $10,000,000. The facility matures on December 16, 2026, and any borrowings will bear interest at one-month Term SOFR plus 1.75%, payable monthly.
The company granted a first-priority security interest in substantially all existing and future assets and agreed to customary covenants, indemnities, and events of default. While amounts are outstanding, Electromed must maintain a minimum Fixed Charge Coverage Ratio of at least 1.20x and a Total Funded Debt to EBITDA ratio of not more than 2.50x, calculated quarterly on a rolling four-quarter basis. Proceeds may be used for capital expenditures, working capital, and general corporate purposes, and the prior credit facility with Choice Financial Group was terminated.
Electromed, Inc. reported an insider equity award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock as an award of restricted stock at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, the director beneficially owns 15,000 shares directly.
The restricted stock is scheduled to vest on June 1, 2026, unless it is accelerated or terminated earlier under its terms, meaning the director’s ability to fully realize the award depends on continued satisfaction of those conditions.
Electromed, Inc. reported an insider equity grant to a director. A board member filed a Form 4 showing an acquisition of 3,000 shares of Electromed common stock on 12/01/2025 at a stated price of $0. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
After this transaction, the director beneficially owned 38,817 shares of Electromed common stock directly and 1,500 shares indirectly through Liberty Capital, LP. The filing notes that the reporting person disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest in them.
Electromed, Inc. reported a Form 4 insider transaction for a company director. On 12/01/2025, the director acquired 3,000 shares of common stock, coded as an "A" transaction, at a reported price of $0, indicating a grant rather than an open-market purchase. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
Following this grant, the director beneficially owned 21,000 shares of Electromed common stock in direct form. The filing is made by a single reporting person in the capacity of Director of Electromed.